NASDAQ:CASI CASI Pharmaceuticals (CASI) Stock Price, News & Analysis $2.28 -0.05 (-2.15%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.28 0.00 (0.00%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CASI Pharmaceuticals Stock (NASDAQ:CASI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CASI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.21▼$2.3650-Day Range$1.22▼$2.4752-Week Range$1.09▼$7.50Volume38,518 shsAverage Volume382,868 shsMarket Capitalization$28.04 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company Overview CASI Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide. The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers. In addition to famitinib, CASI is advancing an immuno-oncology portfolio that includes checkpoint inhibitors and novel immune modulators designed to enhance antitumor responses. Preclinical programs focus on next‐generation molecules with potential applications in both oncology and inflammatory disorders, building on the company’s proprietary discovery platform. Founded by a team of biotech entrepreneurs and scientists, CASI Pharmaceuticals is headquartered in Beijing, with research and development operations in Shanghai and a presence in North America to support global clinical activities. The company has established strategic partnerships with academic institutions and contract research organizations to accelerate its clinical trials and expand its pipeline. CASI’s leadership team comprises industry veterans with extensive experience in drug development and regulatory affairs, guiding the company through key milestones as it pursues regulatory approvals and commercial readiness.AI Generated. May Contain Errors. Read More CASI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCASI MarketRank™: CASI Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 279th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialCASI Pharmaceuticals has a consensus price target of $4.00, representing about 75.4% upside from its current price of $2.28.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about CASI Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 19.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CASI Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.23% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.50 Percentage of Shares Shorted9.23% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CASI Pharmaceuticals has recently increased by 12.78%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.59 News SentimentCASI Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest3 people have searched for CASI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.23% of the stock of CASI Pharmaceuticals is held by institutions.Read more about CASI Pharmaceuticals' insider trading history. Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CASI Stock News HeadlinesCASI announces SMC recommendation to escalate CID-103 dose to next cohortSeptember 8, 2025 | msn.comHC Wainwright Issues Optimistic Estimate for CASI EarningsSeptember 7, 2025 | americanbankingnews.comWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. | Banyan Hill Publishing (Ad)CASI Pharmaceuticals (NASDAQ:CASI) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for CASI Q1 Earnings?September 5, 2025 | americanbankingnews.comCASI Pharmaceuticals stock soars after FDA clearance for transplant drugAugust 5, 2025 | investing.comCASI Pharmaceuticals Stock Surges 12.4% Following FDA Clearance for Transplant DrugAugust 5, 2025 | msn.comCASI Pharmaceuticals Inc Valuation - MorningstarJuly 2, 2025 | morningstar.comMSee More Headlines CASI Stock Analysis - Frequently Asked Questions How have CASI shares performed this year? CASI Pharmaceuticals' stock was trading at $2.83 at the beginning of 2025. Since then, CASI shares have decreased by 19.4% and is now trading at $2.28. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc. (NASDAQ:CASI) released its earnings results on Friday, August, 29th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.39. The biotechnology company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $6.28 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 972.55% and a negative net margin of 148.55%. When did CASI Pharmaceuticals' stock split? CASI Pharmaceuticals's stock reverse split on Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are CASI Pharmaceuticals' major shareholders? Top institutional shareholders of CASI Pharmaceuticals include Foresite Capital Management VI LLC (6.40%). View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/29/2025Today9/13/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CASI CIK895051 Webwww.casipharmaceuticals.com Phone861065086063Fax301-315-2437Employees180Year Founded1991Price Target and Rating Average Price Target for CASI Pharmaceuticals$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+75.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.26 million Net Margins-148.55% Pretax Margin-137.90% Return on Equity-972.55% Return on Assets-99.07% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.39 Sales & Book Value Annual Sales$28.54 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book19.00Miscellaneous Outstanding Shares12,300,000Free Float9,687,000Market Cap$28.04 million OptionableOptionable Beta0.77 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CASI) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.